Investigating melflufen: a peptidase enhanced cytotoxic for myeloma
Paul Richardson • 14 Jun 2018
The challenges of choosing the right target antigen in AML compared to ALL
Marion Subklewe • 4 May 2018
Allogeneic transplant is not the quintessential treatment for ALL anymore!
Sebastian Giebel • 26 Mar 2017
Are combination therapies more effective for the treatment of relapsed refractory CLL?
The combination of BGB-3111 and obinutuzumab for follicular lymphoma: promising preliminary results
Constantine Tam • 14 Jun 2017